On Wednesday, CVS announced strong second-quarter profits; DBV Technologies has submitted its Biologics License Application to the FDA for its treatment for peanut allergy; doctors, health organizations, and students are pushing for medical education to include climate change.
CVS’ deal with Aetna is beginning to pay off, according to the pharmacy chain’s second-quarter profit, which beat expectations. CVS on Wednesday reported $1.94 billion in profit. The company raised its full-year adjustment earnings forecast to $6.89 to $7.00 per share, up from $6.75 to $6.90. According to Reuters, the company is working to bring more healthcare services into its pharmacies and urge Aetna clients to take advantage of cheaper care for chronic conditions as its in-store clinics.
DBV Technologies has submitted its Biologics License Application to the FDA for Viaskin Peanut, its treatment for peanut allergy. The treatment, intended for children aged 4 to 11 years with the allergy, is designed to leverage the skin to activate the immune system and induce desensitization to allergens. In December 2018, DBV voluntarily withdrew its prior submission for the treatment based on additional data needed on manufacturing procedures and quality controls. Yesterday’s submission includes these data.
Backed by the American Medical Association, there is a movement from doctors, health organizations, and students for medical education to include climate change. The groups argue that physicians and other healthcare workers need to prepare for the risks association with rising global temperatures, reported The Wall Street Journal. Some schools have started to show support for the movement; The University of Minnesota’s medical, nursing, and pharmacy schools have added curriculum or tweaked existing courses to incorporate climate-related topics.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen